Parsabiv (Etelcalcetide Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Parsabiv (Etelcalcetide Hydrochloride) by Amgen: FDA Orange Book core substance LOE 2031-02-07 (last listed 2034-06-27), 0 AB generics, $36.4M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmgen
FDA Application & PathwayN208325 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-02-07
Last Listed Patent or Exclusivity Date2034-06-27
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$36.4M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$36.4M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 16.8% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.